[go: up one dir, main page]

WO2021222971A1 - Traitement du syndrome de détresse respiratoire aiguë induite par un virus - Google Patents

Traitement du syndrome de détresse respiratoire aiguë induite par un virus Download PDF

Info

Publication number
WO2021222971A1
WO2021222971A1 PCT/AU2021/050403 AU2021050403W WO2021222971A1 WO 2021222971 A1 WO2021222971 A1 WO 2021222971A1 AU 2021050403 W AU2021050403 W AU 2021050403W WO 2021222971 A1 WO2021222971 A1 WO 2021222971A1
Authority
WO
WIPO (PCT)
Prior art keywords
ccr2
pathway inhibitor
blocker
treatment
ards
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2021/050403
Other languages
English (en)
Inventor
Robert Shepherd
Nina WEBSTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimerix Bioscience Ltd
Original Assignee
Dimerix Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimerix Bioscience Ltd filed Critical Dimerix Bioscience Ltd
Publication of WO2021222971A1 publication Critical patent/WO2021222971A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Acute respiratory distress syndrome is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. The underlying mechanism involves diffuse injury to cells which form the barrier of the microscopic air sacs of the lungs, surfactant dysfunction, activation of the immune system, and dysfunction of the body's regulation of blood clotting.
  • Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • WHO World Health Organization declared the 2019–20 coronavirus outbreak a pandemic in March 2020. People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
  • the present invention provides a method for the treatment, amelioration or prevention of ARDS, said method comprising the step of: i) administering to a subject a therapeutically effective amount of a chemokine receptor 2 (CCR2) pathway inhibitor.
  • CCR2 chemokine receptor 2
  • the present invention also provides a method for the treatment, amelioration or prevention of ARDS, said method comprising the step of: i) administering to a subject a therapeutically effective amount of (a) an angiotensin type 1 receptor (AT 1 R) blocker and (b) a chemokine receptor 2 (CCR2) pathway inhibitor.
  • the ARDS is associated with (i) infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and/or (ii) coronavirus disease 2019 (COVID-19).
  • the CCR2 pathway inhibitor is propagermanium and/or the AT 1 R blocker is chosen from the group comprising: irbesartan, eprosartan, losartan, valsartan, telmisartan, candesartan, olmesartan, and ZD-7115.
  • CCR2 pathway inhibitors include pharmaceutically acceptable salts of CCR2 pathway inhibitors.
  • AT 1 R blockers include pharmaceutically acceptable salts of AT 1 R blockers.
  • the CCR2 pathway inhibitor and the AT 1 R blocker may be administered in the same dosage form or in separate dosage forms. [0012] The CCR2 pathway inhibitor and the AT 1 R blocker may be administered concurrently or sequentially. [0013] The invention also provides for the use of at least one chemokine receptor 2 (CCR2) pathway inhibitor for the manufacture of a dosage form for the treatment or prevention of ARDS. [0014] The invention also provides for the use of (a) at least one angiotensin type 1 receptor (AT 1 R) blocker, and (b) at least one chemokine receptor 2 (CCR2) pathway inhibitor for the manufacture of a dosage form for the treatment or prevention of ARDS.
  • the present invention provides a kit for the treatment, amelioration or prevention of ARDS, said kit comprising: a) at least one chemokine receptor 2 (CCR2) pathway inhibitor; and b) instructions for use.
  • the present invention provides a kit for the treatment, amelioration or prevention of ARDS, said kit comprising: a) at least one angiotensin type 1 receptor (AT 1 R) blocker; b) at least one chemokine receptor 2 (CCR2) pathway inhibitor; and c) instructions for use.
  • the present invention provides at least one CCR2 pathway inhibitor, for use in a formulation for the treatment, amelioration or prevention of ARDS.
  • the present invention provides at least one AT 1 R blocker, and at least one CCR2 pathway inhibitor, for use in a formulation for the treatment, amelioration or prevention of ARDS.
  • the present invention provides at least one AT 1 R blocker for use in a formulation for the treatment, amelioration or prevention of ARDS, wherein the at least one AT 1 R blocker is administered to the subject concurrently or sequentially with at least one CCR2 pathway inhibitor.
  • the present invention provides at least one CCR2 pathway inhibitor for use in a formulation for the treatment, amelioration or prevention of ARDS wherein the at least one CCR2 pathway inhibitor is administered to the subject concurrently or sequentially with at least one AT 1 R blocker.
  • RAAS dysregulation The Renin-Angiotensin-Aldosterone System (RAAS) consists of an enzymatic cascade beginning with liver-mediated production of angiotensinogen (AGT), the precursor of angiotensin (Ang) peptides.
  • AGT angiotensinogen
  • Ang II the main effector of this system, results from successive enzymatic actions of renin and angiotensin-converting enzyme (ACE) and exerts most of its actions through activation of Ang II type 1 and type 2 receptors (AT 1 R and AT 2 R, respectively).
  • AT 1 R mediates the pathogenic actions of Ang II
  • activated AT 2 R elicits protective effects.
  • RAAS Renin-Angiotensin-Aldosterone System
  • MCP-1 the ligand for chemokine receptor 2 and an element of the RAAS system
  • VAP ventilator-assisted pneumonia
  • Plasma MCP-1 levels are significantly increased in the acute stage in VAP patients when compared with patients without VAP and a control group.
  • Plasma MCP-1 levels decreased after treatment but were still significantly increased even in the remission stage of VAP patients when compared with non-VAP subjects and healthy controls.
  • the plasma MCP-1 levels were also significantly increased in VAP patients who developed ARDS when compared with patients without ARDS, healthy controls, and non-VAP subjects (Li et al., 2019).
  • ACE inhibitors and AT 1 R inhibitors [0026] The present inventors have identified that the binding partner for SARS-CoV is ACE2 (Kuba, et al., 2005), another element of the RAAS system. Infections with SARS-CoV result in ACE2 downregulation through binding of SARS-CoV Spike protein to ACE2. Given that ACE2 is a key negative regulatory factor for severity of lung oedema and acute lung failure, SARS-CoV Spike protein–mediated ACE2 downregulation then contributes to the severity of lung pathologies. [0027] The inventors have noted a molecular link between the pathogenesis of the original SARS virus and the role of the RAAS system in lung failure.
  • the AT 1 R inhibitor losartan was also found to attenuate acute severe lung injury in Spike-Fc–treated mice and inhibition of the AT 1 R also attenuated pulmonary oedema (Kuba, et al., 2005).
  • the inventors have also recognised that Covid-19 patients with existing hypertension who were being treated with an ACE inhibitor or AT 1 R at the time of admission had a much lower proportion of critical patients and a lower death rate (Guang, et al., 2020).
  • SARS-CoV-2 binding to ACE2 may dysregulate the RAAS system by attenuating residual ACE2 activity, further tipping the ACE/ACE2 balance to a predominant ACE/AngII/AT1 axis signalling, in which AngII may then foster pulmonary vasoconstriction, and inflammatory and oxidative organ damage, ultimately progressing towards ARDS (Sanchis-Gomar, et al., 2020).
  • CCR2 pathway inhibitors [0030] Chemokine receptor 2 (CCR2) is another element of the RAAS system.
  • CCR2 inhibition is central in control of a range of inflammatory diseases, although to date CCR2 inhibition programs have only been associated with chronic (not acute) inflammatory diseases such as renal disease.
  • CCR2 inhibition programs have only been associated with chronic (not acute) inflammatory diseases such as renal disease.
  • models of inflammatory renal disease (Ayoub et al., 2015), the inventors have shown that there is a decreased infiltration of monocytes to the damaged kidney, and decreased fibrosis when treated with an AT 1 R blocker and a CCR2 pathway inhibitor.
  • cells such as activated monocytes, where chemotaxis to areas of inflammation is driven by a cline in MCP-1 (also known as CCL2), inhibition of CCR2 alone or in addition to AT 1 R, inhibits this chemotaxis.
  • MCP-1 also known as CCL2
  • the present invention provides a pharmaceutical formulation comprising: a) at least one chemokine receptor 2 (CCR2) pathway inhibitor.
  • the present invention provides a pharmaceutical formulation comprising: a) at least one angiotensin type 1 receptor (AT 1 R) blocker; and b) at least one chemokine receptor 2 (CCR2) pathway inhibitor.
  • the pharmaceutical formulation may optionally include excipients, solvents, carriers and other pharmaceutically acceptable ingredients.
  • CCR2 Chemokine receptor 2
  • CCR2 is a G-protein coupled receptor.
  • chemokine receptor 2 pathway is to be understood to include any one of the pathways of the chemokine receptor 2 activated by its native ligands, including but not limited to those pathways that cause chemotactic migration, cell motility, extracellular-regulated kinase (ERK) phosphorylation, cAMP production, actin-recruitment, protein phosphorylation, nuclear protein localization, gene transcription or translation, G protein coupling, ⁇ -arrestin recruitment or mediated signalling.
  • chemokine receptor 2 pathway inhibitor is intended to include any compound or agent which inhibits or partially inhibits any one of the pathways associated with the chemokine receptor 2.
  • the chemokine receptor pathway inhibitor may be a peptide, polypeptide or small chemical entity.
  • the chemokine receptor 2 pathway inhibitor may be a protein, binding protein or antibody.
  • the phrase “chemokine receptor 2 pathway inhibitor” includes compounds or agents which inhibit or partially inhibit the chemokine receptor 2 itself.
  • such chemokine receptor 2 pathway inhibitors are selected from: a direct CCR2 antagonist, a direct CCR2 inverse agonist or a direct CCR2 negative allosteric modulator.
  • chemokine receptor 2 pathway inhibitor includes compounds or agents which inhibit or partially inhibit a component of the chemokine receptor pathway other than the chemokine receptor 2 itself.
  • the inhibitor may inhibit or partially inhibit proteins that associate with chemokine receptor 2 or may inhibit compounds or pathway steps before and/or after the chemokine receptor itself.
  • the chemokine receptor 2 pathway inhibitors are selected from: an indirect CCR2 antagonist, an indirect CCR2 inverse agonist or an indirect CCR2 negative allosteric modulator.
  • the term “a component of the chemokine receptor pathway other than the chemokine receptor 2 itself” as used herein, is to be understood to refer a component of the chemokine receptor 2 pathway wherein the component is itself not the chemokine receptor 2.
  • the component of the chemokine receptor pathway may interact directly with chemokine receptor 2.
  • the component of the chemokine receptor pathway may interact indirectly with chemokine receptor 2 by way of protein-protein interaction or complex formation.
  • the component of the chemokine receptor pathway may interact indirectly with chemokine receptor 2 by way of a signalling cascade.
  • the component is a protein such as, but not limited to a transduction or signalling protein
  • the chemokine receptor pathway inhibitor inhibits or partially inhibits a component of the pathway other than the chemokine receptor 2 itself, the inhibitor blocks MCP- 1 induced migration and activation of monocytes and chemotactic migration through the targeting of glycosylphosphatidylinositol (GPI)-anchored proteins such as CD55, CD59 and CD16.
  • GPI glycosylphosphatidylinositol
  • the inhibited component is MCP-1.
  • the chemokine receptor 2 pathway inhibitor inhibits or partially inhibits the in vitro chemotactic migration of monocytes induced by MCP-1 by targeting MCP-1 directly.
  • MCP-1 is a ligand for chemokine receptor 2.
  • Such compounds include agents which bind MCP-1.
  • the chemokine receptor pathway inhibitor inhibits or partially inhibits a component of the pathway other than the chemokine receptor 2, the inhibited component is chosen from the list of CCR2 ligands comprising: CCL7 (MCP-3), CCL8, CCL13 (MCP-4), and CCL16 [hemofiltrate CC chemokine (HCC)-4].
  • the chemokine receptor 2 pathway inhibitor inhibits or partially inhibits the in vitro chemotactic migration of monocytes induced by the above CCR2 ligands by targeting the ligands directly.
  • Such compounds include agents which bind CCL7, CCL8, CCL13, and CCL16.
  • the chemokine receptor 2 pathway inhibitor inhibits or partially inhibits the in vitro chemotactic migration of monocytes induced by MCP-1 by targeting one or more GPI-anchored proteins selected from the group comprising CD55, CD59 and CD16.
  • the chemokine receptor pathway inhibitor may stabilize the complexes CCR2/CD55 and/or CCR2/CD59 and/or CCR2/CD16.
  • chemokine receptor 2 pathway inhibitor is a direct antagonist of chemokine receptor 2, such as propagermanium, repagermanium or CCX140.
  • Propagermanium (3-oxygermylpropionic acid polymer), is a molecule that has been used as a therapeutic agent against chronic hepatitis, also has been shown to specifically inhibit in vitro chemotactic migration of monocytes by MCP-1 through a mechanism that seems to require glycosylphosphatidylinositol (GPI)-anchored proteins such as CD55, CD59 and CD16 (Yokochi, S. 2001).
  • GPI glycosylphosphatidylinositol
  • Propagermanium is also known as 3-[(2-Carboxyethyl-oxogermyl)oxy- oxogermyl]propanoic acid, proxigermanium, Ge-132, bis (2- carboxyethylgermanium) sesquioxide (CEGS), 2-carboxyethylgermasesquioxane, SK-818, organic germanium, germanium sesquioxide, 3,3 ⁇ '>-(1,3-dioxo-1,3-digermanoxanediyl) bispropionic acid, 3- oxygermylpropionic acid polymer, poly- fra/7s-(2-carboxyethyl) germasesquioxane, proxigermanium, repagermanium and SerocionTM.
  • angiotensin type 1 receptor (AT 1 R, AT1R, angiotensin II receptor type 1) is a G protein-coupled receptor.
  • angiotensin type 1 receptor blocker (also referred to as AT 1 R blocker or ARB) is understood to include any compound or agent which inhibits or partially inhibits the activation of AT 1 R.
  • the AT 1 R blocker may be selected from the group comprising: irbesartan (e.g. Avapro®), eprosartan (e.g. Teveten®), losartan (e.g. Cozaar®), valsartan (e.g. Diovan®), telmisartan (e.g.
  • Micardis® candesartan (e.g. Atacand®), olmesartan (e.g. Benicar®), Azilsartan (e.g. Edarbi) and ZD-7115.
  • Taylor et al (2011) reviews AT 1 R blockers and noted that “[t]here are no major differences in efficacy or other clinical characteristics among older drugs in this class, although some of the newer agents may more effectively reduce blood pressure than the older agents”. The differences in characteristics appear to be related to interaction with other pathways and not the core angiotensin type 1 receptor blockage.
  • the angiotensin receptor inhibitor may be irbesartan.
  • Irbesartan is an angiotensin type 1 receptor antagonist also known as 2-butyl-3-( ⁇ 4-[2-(2H-1,2,3,4-tetrazol-5- yl)phenyl]phenyl ⁇ methyl)-1,3-diazaspiro[4.4]non-1-en-4-one.
  • Both the AT 1 R blocker and the CCR2 pathway inhibitor may be pharmaceutically acceptable salts of the respective active agent.
  • Pharmaceutically and veterinary acceptable salts include salts which retain the biological effectiveness and properties of the compounds of the present disclosure and which are not biologically or otherwise undesirable.
  • the compounds disclosed herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as by way of example only, alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(subsrituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amines, trisubstituted cycloalkyl amines, cycloalkenyl amines
  • amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group.
  • Pharmaceutically and veterinary acceptable acid addition salts may be prepared from inorganic and organic acids.
  • the inorganic acids that can be used include, by way of example only, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • the organic acids that can be used include, by way of example only, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • the pharmaceutically or veterinary acceptable salts of the compounds useful in the present disclosure can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences. 17th ed., Mack Publishing Company, Easton, Pa. (1985), p.
  • salts are the iodide, acetate, phenyl acetate, trifluoroacetate, acryl ate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybsnzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2- benzoate, bromide, isobutyrate, phenylbutyrate, y-hydroxybutyrate, ⁇ -hydroxybutyrate, butyne- l,4-dioate, hexyne-l,4-dioate, hexyne- 1 ,6-dioate, caproate, caprylate, chloride, cinnamate, citrate, decan oate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate,
  • the CCR2 pathway inhibitor and/or the AT 1 R blocker are for use in the treatment, amelioration or prevention of ARDS.
  • ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. The most common cause of ARDS is sepsis; however, ARDS may also be triggered by lung infections such as severe pneumonia.
  • ARDS may be found in subjects with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • COVID-19 coronavirus disease 2019
  • prevention includes administration of the compositions of the present invention to subjects who have symptoms that indicate they are at risk of developing ARDS, but may not, at the time of treatment, be diagnosed with ARDS.
  • the subject may have severe persistent cough and/or low oxygen levels, but not be diagnosed with ARDS.
  • adjuoration includes administration of the compositions of the present invention to subjects who have had ARDS and are at risk of developing post-ARDS conditions such as fibrosis and persistent inflammation.
  • the post-ARDS conditions may be due to the ARDS itself or may be due to the use of ventilators during the acute phase of ARDS.
  • angiotensin type 1 receptor blocker is understood to include any compound or agent which inhibits or partially inhibits the activation of AT 1 R.
  • chemokine receptor 2 pathway inhibitor is intended to include any compound or agent which inhibits or partially inhibits any one of the pathways associated with the chemokine receptor 2.
  • inhibitors means a reduction below detectable limits when compared to a reference.
  • the phrase includes blocking, retarding, or impeding an action to prevent an undesirable result.
  • partially inhibits as used herein, means any reduction within detectable limits when compared to a reference.
  • the phrase includes blocking, retarding, or impeding an action to prevent an undesirable result.
  • the inhibition or partial inhibition of the CCR2 pathway and/or the AT 1 R caused by (i) the CCR2 pathway inhibitor, (ii) the AT 1 R blocker, or (iii) both the CCR2 pathway inhibitor and the AT 1 R blocker may be measured using the in vitro methods set out herein, and include but are not limited to, biochemical or cellular assays for the assessment of in vitro chemotactic migration of CCR2-expressing neutrophils and other cells such as are known in the art, as well as measurement of inositol phosphate production, extracellular-regulated kinase (ERK) phosphorylation, cAMP production, actin-recruitment, protein phosphorylation, nuclear protein localization, gene transcription, label-free technologies (such as using impedance, light refraction or charge redistribution), G protein coupling using proximity reporter systems or other approaches, ⁇ -arrestin recruitment or mediated signal
  • the inhibition or partial inhibition of the CCR2 pathway and/or the AT 1 R caused by (i) the CCR2 pathway inhibitor, (ii) the AT 1 R blocker, or (iii) both the CCR2 pathway inhibitor and the AT 1 R blocker may be measured using the in vivo methods set out herein, and include but are not limited to, measurement of cellular and cytokine content of lung exudate, measurement of lung function including physical capacity of lung function using spirometry-based tests, or lung functional outputs measured using measurement blood gas or other biochemical measures, or improvement in functional benefit including clinical benefit measured by quantitative methods such as walk tests or qualitative methods such as patient-reported outcome assessment.
  • the total efficacy of the pharmaceutical formulation is greater when compared to the efficacies of the AT 1 R blocker or the CCR2 pathway inhibitor when either component is administered without any administration of the other component.
  • the combined formulation may be administered in a single dose, including at sub-therapeutic doses, or less often, than either of the two components might be administered as single compounds.
  • the total efficacy of the pharmaceutical formulation is greater when compared to the sum of the efficacies of the AT 1 R blocker and the CCR2 pathway inhibitor when either component is administered without any administration of the other component.
  • the total efficacy of the pharmaceutical formulation is equal to the sum of the efficacies of the AT 1 R blocker and the CCR2 pathway inhibitor when either component is administered without any administration of the other component.
  • an additive effect in efficacy is observed when the AT 1 R blocker and the CCR2 pathway inhibitor are administered concurrently or sequentially.
  • the total efficacy of the pharmaceutical formulation is less than the sum of the efficacies of the AT 1 R blocker and the CCR2 pathway inhibitor when either component is administered without any administration of the other component.
  • the treatment provides greater efficacy compared to a single treatment of AT 1 R blocker or the CCR2 pathway inhibitor administered alone.
  • the two components are administered concurrently at the same time (for example as two tablets taken together, or as a single tablet, formulated with each component) or sequentially (for example one tablet taken after another tablet).
  • the doses of each component may be taken together (concurrently), or sequentially and taken within seconds, minutes, days, weeks or months of each other.
  • the invention provides a method for treatment, amelioration or prevention of ARDS, said method comprising the step of: i) administering to a subject a therapeutically effective amount of a chemokine receptor 2 (CCR2) pathway inhibitor.
  • the invention further provides a method for treatment, amelioration or prevention of ARDS, said method comprising the step of: i) administering to a subject a therapeutically effective amount of (a) an angiotensin type 1 receptor (AT 1 R) blocker, and (b) a chemokine receptor 2 (CCR2) pathway inhibitor.
  • the subject to be treated is preferably a mammal, including a human mammal.
  • the ARDS is associated with (i) infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and/or (ii) coronavirus disease 2019 (COVID-19).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • COVID-19 coronavirus disease 2019
  • the CCR2 pathway inhibitor may be administered alone, as a single therapy.
  • the CCR2 pathway inhibitor and the AT 1 R blocker may be administered: in the same dosage form or in separate dosage forms.
  • the CCR2 pathway inhibitor and the AT 1 R blocker may be administered: concurrently or sequentially.
  • the CCR2 pathway inhibitor and/or the AT 1 R blocker may be pharmaceutically acceptable salts of the CCR2 pathway inhibitor and/or the AT 1 R blocker.
  • the second component of the treatment of the present invention is administered as a second component in therapy to provide the therapy of the present invention.
  • the CCR2 pathway inhibitor has a greater affinity and/or potency and/or efficacy when interacting with the CCR2 or modulating its downstream pathways when the CCR2 is associated with the angiotensin receptor.
  • the CCR2 and the angiotensin receptor may be associated as a CCR2/AT 1 R hetero-dimer/-oligomer.
  • the combined affinity, potency and/or efficacy is greater than compared to the affinity, potency and/or efficacy that would have been achieved when the CCR2 pathway inhibitor is not administered (whether concurrently or sequentially) with the AT 1 R blocker.
  • a synergistic effect is achieved when the CCR2 pathway inhibitor is administered to a subject (whether [0085] While not intending to be restricted to any particular mode of action, in one preferred embodiment the AT 1 R blocker has a greater affinity and/or potency and/or efficacy when interacting with the angiotensin receptor when the angiotensin receptor is associated with the CCR2.
  • the CCR2 and the angiotensin receptor may be associated as a CCR2/ AT 1 R hetero-dimer/-oligomer.
  • the combined affinity, potency and/or efficacy is greater than compared to the affinity, potency and/or efficacy that would have been achieved when the AT 1 R blocker is not administered (whether concurrently or sequentially) with the CCR2 pathway inhibitor.
  • a synergistic effect is achieved when the AT 1 R blocker is administered to a subject (whether concurrently or sequentially) with a CCR2 pathway inhibitor.
  • the dosage form provided by the present invention may further comprise a vial, cartridge, container, tablet or capsule comprising the pharmaceutical formulation of the invention together with dosage instructions for the administration of the dosage form(s) to a subject for the treatment, amelioration or prevention of ARDS.
  • each active ingredient which may be combined with the carrier materials to produce a single dosage will vary, depending upon the host to be treated and the particular mode of administration.
  • a formulation intended for oral administration to humans may contain about 0.5mg to 1 g of each active compound with an appropriate and convenient amount of carrier material, which may vary from about 5 to 95 % w/w of the total formulation.
  • Dosage unit forms will generally contain between from about 0.5mg to 1000mg of active ingredient(s).
  • the CCR2 pathway inhibitor is provided at between 0.5mg to 2000mg per day, provided in one or more doses. Even more preferably the CCR2 pathway inhibitor is provided at a dose of between 0.5mg to 50mg per day, provided in one or more doses.
  • the AT 1 R blocker may be provided at between 50mg to 500mg per day, provided in one or more doses.
  • the AT 1 R blocker may be provided at between 75mg to 300mg per day.
  • the AT 1 R blocker may be irbesartan and is administered at a dose of 75, 150 or 300mg per day, provided in one or more doses.
  • the AT 1 R blocker is provided at between 1 mg to 1200mg per day, provided in one or more doses.
  • the AT 1 R blocker is provided at between 1 mg to 1200mg per day, provided in one or more doses.
  • the AT 1 R blocker is provided at between 1 mg to 1200mg per day, provided in one or more doses.
  • the AT 1 R blocker is irbesartan and it is administered in an individual dose of 75, 150 or 300mg, provided one or more times per day; • the AT 1 R blocker is eprosartan mesylate and it is administered in an individual dose of 300mg, 400mg or 600mg, provided one or more times per day; • the AT 1 R blocker is losartan potassium and it is administered in an individual dose of 25mg, 50mg or 100mg, provided one or more times per day; • the AT 1 R blocker is valsartan and it is administered in an individual dose of 80mg, 160mg or 320mg, provided one or more times per day; • the AT 1 R blocker is telmisartan and it is administered at a dose of 20mg, 40mg or 80mg, provided one or more times per day; • the AT 1 R blocker is candesartan cilexetil and it is administered in an individual dose of 4mg, 8mg, 16mg or 32m
  • each active agent may be provided in either a single dosage form, or two separate dosage forms.
  • the actives may be provided as about 0.5mg to 1g of the CCR2 pathway inhibitor and about 1mg to 1200mg of the AT 1 R blocker.
  • the dose of the two actives may be provided in either a single dosage form, or two separate dosage forms and may comprise (i) a daily dose of AT 1 R blocker of between about 1mg to 1200mg, and (ii) a daily dose of CCR2 pathway inhibitor of between about 5mg to 50mg.
  • the AT 1 R blocker may be irbesartan, and the dosage form may comprise a daily dose of irbesartan of about 300mg.
  • Table 1 Examples of combinations of preferred active agents: [0094]
  • the repagermanium and the AT 1 R blocker are provided as once daily doses.
  • the repagermanium and the AT 1 R blocker are provided as twice daily doses.
  • the repagermanium is provided as a twice daily dose (BID) and the AT 1 R blocker is administered as a single daily dose.
  • BID twice daily dose
  • AT 1 R blocker is administered as a single daily dose.
  • the specific dose level for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, combinations of drugs, and the severity of the particular condition or disease undergoing therapy.
  • Formulations of the invention in various aspects, may be administered by injection, or prepared for oral, pulmonary, nasal or for any other form of administration.
  • the formulations are administered, for example, intravenously, subcutaneously, intramuscularly, intraorbitally, ophthalmically, intraventricularly, intracranially, intracapsularly, intraspinally, intracisternally, intraperitoneally, buccal, rectally, vaginally, intranasally or by aerosol administration.
  • the mode of administration is in one aspect at least suitable for the form in which the formulation has been prepared.
  • the mode of administration for the most effective response may be determined empirically and the means of administration described below are given as examples, and do not limit the method of delivery of the formulation of the present invention in any way. All the formulations provided are commonly used in the pharmaceutical industry and are commonly known to suitably qualified practitioners.
  • the formulations of the invention in certain aspects may include pharmaceutically acceptable non-toxic excipients and carriers and administered by any parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections.
  • the formulations may optionally contain one or more adjuvants.
  • a "pharmaceutical carrier” is a pharmaceutically acceptable solvent, suspending agent, excipient or vehicle for delivering the compounds to the subject.
  • the carrier may be liquid or solid and is selected with the planned manner of administration in mind.
  • the pharmaceutical forms suitable for injectable use optionally include sterile aqueous solutions (where water-soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the compounds of the invention are, in certain aspects encapsulated in liposomes and delivered in injectable solutions to assist their transport across cell membrane.
  • such preparations contain constituents of self-assembling pore structures to facilitate transport across the cellular membrane.
  • the carrier in various aspects, is a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • Proper fluidity is maintained, for example and without limitation, by a coating such as lecithin; by the maintenance of the required particle size in the case of dispersion; and by the use of surfactants.
  • the invention also provides prolonged absorption of an injectable sustained release pharmaceutical formulation comprising a therapeutically effective pharmaceutical formulation according to the invention and a release retardant.
  • the release retardant may be, for example, aluminium mono-stearate and gelatine.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in an appropriate solvent with one or more of the other ingredients enumerated above, as required, followed by filtered sterilisation.
  • dispersions are prepared by incorporating the various sterilised active ingredient into a sterile vehicle that contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • preparation in certain aspects include without limitation vacuum drying and freeze- drying techniques that yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • oral dosage forms which are described generally in Martin, Remington's Pharmaceutical Sciences, 18th Ed. (1990 Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference.
  • Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, liquids, suspensions or pellets.
  • liposomal or proteinoid encapsulation may be used to formulate the present formulations (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673).
  • Liposomal encapsulation may be used, and the liposomes may be derivatised with various polymers (E.g., U.S. Patent No. 5,013,556).
  • the oral dosage form of the present invention may be a liquid, suspension or other appropriate dosage form that is delivered directly into the feeding tube of a patient who is in a coma and/or on a respirator and is unable to swallow a tablet etc.
  • the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine.
  • the small intestine the duodenum, the jejunum, or the ileum
  • the release will avoid the deleterious effects of the stomach environment, either by protection of the formulation or by release of the compounds beyond the stomach environment, such as in the intestine.
  • a coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This includes without limitation sugar coatings, or coatings that make the tablet easier to swallow.
  • Exemplary capsules consist of a hard shell (such as gelatine) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatine shell may be used.
  • the shell material of cachets in certain aspects is thick starch or other edible paper.
  • moist massing techniques are also contemplated, without limitation.
  • sustained release means the gradual but continuous or sustained release over a relatively extended period of the therapeutic compound content after oral ingestion. The release may continue after the pharmaceutical formulation has passed from the stomach and through until and after the pharmaceutical formulation reaches the intestine.
  • sustained release also means delayed release wherein release of the therapeutic compound is not immediately initiated upon the pharmaceutical formulation reaching the stomach but rather is delayed for a period of time, for example, until when the pharmaceutical formulation reaches the intestine. Upon reaching the intestine, the increase in pH may then trigger release of the therapeutic compound from the pharmaceutical formulation.
  • release retardant means a substance that reduces the rate of release of a therapeutic compound from a pharmaceutical formulation when orally ingested.
  • the release retardant may be a polymer or a non-polymer.
  • the release retardant may be used according to any one of several sustained release systems including, for example, a diffusion system, a dissolution system and/or an osmotic system.
  • the therapeutic is included in the formulation as fine multi- particulates in the form of granules or pellets of particle size about 1mm.
  • the formulation of the material for capsule administration is, in certain aspects, a powder, lightly compressed plugs or even as tablets.
  • the therapeutic could be prepared by compression.
  • Colourants and flavouring agents are optionally all be included.
  • compounds may be formulated (such as, and without limitation, by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavouring agents.
  • the volume of the therapeutics in one aspect, is diluted or increased with an inert material.
  • diluents could include carbohydrates, especially mannitol, alpha-lactose, anhydrous lactose, lactose monohydrate, cellulose, silicified microcrystalline cellulose, sucrose, modified dextrans and starch. Certain inorganic salts are also optionally used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell. [00111] In other embodiments, disintegrants are included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab.
  • Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatine, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite are also contemplated.
  • Another form of the disintegrants is the insoluble cationic exchange resins.
  • Powdered gums are also optionally used as disintegrants and as binders and these include, without limitation, powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt and crospovidone are also useful as disintegrants.
  • Binders are contemplated to hold the therapeutic compounds together to form a hard tablet and include, without limitation, materials from natural products such as acacia, tragacanth, starch and gelatine.
  • Other binders include, without limitation, methylcellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC), silicified microcrystalline cellulose (SMCC), polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC).
  • MC methylcellulose
  • EC ethyl cellulose
  • CMC carboxymethyl cellulose
  • SMCC silicified microcrystalline cellulose
  • PVP polyvinyl pyrrolidone
  • HPMC hydroxypropylmethyl cellulose
  • Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) are also contemplated for use in alcoholic solutions to granulate the therapeutic.
  • An antifrictional agent may be optionally included in the formulation of the therapeutic to prevent sticking during the formulation process.
  • Lubricants may be optionally used as a layer between the therapeutic and the die wall, and these can include but are not limited to: stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes.
  • Exemplary soluble lubricants may also be used such as include sodium lauryl sulfate, magnesium lauryl sulfate, sodium stearyl fumarate, polyethylene glycol of various molecular weights, and Carbowax 4000 and 6000.
  • Glidants that might improve the flow properties of the compound during formulation and to aid rearrangement during compression might be optionally added.
  • the glidants may include without limitation starch, talc, pyrogenic silica and hydrated silicoaluminate.
  • a surfactant might be added in certain embodiments as a wetting agent.
  • Surfactants may include, for example and without limitation, anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate.
  • Cationic detergents might be optionally used and could include, without limitation, benzalkonium chloride or benzethomium chloride.
  • the list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. When used, these surfactants could be present in the formulation of the compounds either alone or as a mixture in different ratios.
  • Additives that potentially enhance uptake of the compounds are for instance and without limitation the fatty acids oleic acid, linoleic acid and linolenic acid.
  • Controlled release formulation may be desirable.
  • the formulations are also contemplated.
  • the compounds could be incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms i.e., gums.
  • slowly degenerating matrices may also be incorporated into the formulation.
  • Another form of a controlled release of this therapeutic is by a method based on the Oros therapeutic system (Alza Corp.), i.e.
  • the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.
  • Film coating may be carried out, for example and without limitation, in a pan coater or in a fluidized bed or by compression coating.
  • Pulmonary and nasal dosage forms are also contemplated herein.
  • the CCR2 pathway inhibitor or the AT 1 R blocker may be delivered to the lungs of a subject while inhaling and traverses across the lung epithelial lining to the blood stream.
  • Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered-dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
  • Some specific examples of commercially available devices suitable for the practice of this invention are, for example and without limitation, the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colorado; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts.
  • formulations suitable for the dispensing of the compounds require the use of formulations suitable for the dispensing of the compounds.
  • each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and/or carriers useful in therapy.
  • liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.
  • Formulations suitable for use with a nebulizer, either jet or ultrasonic will typically comprise the compounds suspended in water.
  • the formulation may also include, in one aspect, a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure).
  • the nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the compounds caused by atomization of the solution in forming the aerosol.
  • Formulations for use with a metered dose inhaler device will generally comprise, in one aspect a finely divided powder containing the compounds suspended in a propellant with the aid of a surfactant.
  • the propellant may be is any conventional material employed for this purpose, such as and without limitation, a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2 tetrafluoroethane, or combinations thereof.
  • Suitable surfactants include, without limitation sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant in certain aspects.
  • Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the compound and may also include a bulking agent, such as and without limitation lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
  • the compound(s) is/are prepared in particulate form with an average particle size of less than 10 microns, most preferably 0.5 to 5 microns, for most effective delivery to the distal lung.
  • Nasal delivery of the compounds is also contemplated.
  • Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung.
  • Formulations for nasal delivery include those with, for example and without limitation, dextran or cyclodextran.
  • Dosing schedule [00127] It will be appreciated that in certain aspects, the formulations of the invention may be given as a single dose schedule, or preferably, in a multiple dose schedule. A multiple dose schedule is one in which a primary course of delivery may be with 1 to 10 separate doses, is optionally followed by other doses given at subsequent time intervals required to maintain or reinforce the treatment. The dosage regimen will also, at least in part, be determined by the needs of the individual and the judgement of the practitioner.
  • the invention thus provides a tablet comprising the pharmaceutical formulation of the invention; a capsule comprising the pharmaceutical formulation of the invention, an injectable suspension comprising the pharmaceutical formulation of the invention, and a formulation for pulmonary delivery comprising the pharmaceutical formulation of the invention.
  • the AT 1 R blocker and the CCR2 pathway inhibitor may be delivered in the same formulation or may be delivered in separate formulations.
  • the AT 1 R blocker and the CCR2 pathway inhibitor may be in the same dosage form or may be in separate dosage forms.
  • the subject being administered the AT 1 R blocker and the CCR2 pathway inhibitor may be already receiving one of the active agents and may, in accordance with the present invention, be administered the other component of the treatment of the present invention.
  • the treatment of the present invention may comprise the administration of only a CCR2 pathway inhibitor.
  • the invention also provides for the use of a pharmaceutical formulation comprising at least one chemokine receptor 2 (CCR2) pathway inhibitor for the manufacture of a formulation for the treatment, amelioration or prevention of ARDS.
  • CCR2 pathway inhibitor for use in a formulation for the treatment, amelioration or prevention of ARDS.
  • the invention also provides for the use of a pharmaceutical formulation comprising (a) at least one angiotensin type 1 receptor (AT 1 R) blocker, and (b) at least one chemokine receptor 2 (CCR2) pathway inhibitor for the manufacture of a formulation for the treatment, amelioration or prevention of ARDS.
  • the present invention further provides at least one AT 1 R blocker, and at least one CCR2 pathway inhibitor, for use in a formulation for the treatment, amelioration or prevention of ARDS.
  • the present invention further provides at least one AT 1 R blocker for use in a formulation for the treatment, amelioration or prevention of ARDS wherein the at least one AT 1 R blocker is administered to the subject concurrently or sequentially with at least one CCR2 pathway inhibitor.
  • the present invention further provides at least one CCR2 pathway inhibitor for use in a formulation for the treatment, amelioration or prevention of ARDS wherein the at least one CCR2 pathway inhibitor is administered to the subject concurrently or sequentially with at least one AT 1 R blocker.
  • the formulation is for use in the treatment, amelioration or prevention of ARDS.
  • ARDS is associated with (i) infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and/or (ii) coronavirus disease 2019 (COVID-19).
  • SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
  • COVID-19 coronavirus disease 2019 (COVID-19).
  • the CCR2 pathway inhibitor and the AT 1 R blocker may be administered: in the same dosage form or in separate dosage forms.
  • the CCR2 pathway inhibitor and the AT 1 R blocker may be administered: concurrently or sequentially.
  • the CCR2 pathway inhibitor and/or the AT 1 R blocker may be pharmaceutically acceptable salts of the CCR2 pathway inhibitor and/or the AT 1 R blocker.
  • kits [00139] The present invention provides a kit for the treatment or prevention of ARDS, said kit comprising: a) at least one chemokine receptor 2 (CCR2) pathway inhibitor; and b) instructions for use.
  • the present invention provides a kit for the treatment or prevention of ARDS, said kit comprising: a) at least one angiotensin type 1 receptor (AT 1 R) blocker; b) at least one chemokine receptor 2 (CCR2) pathway inhibitor; and c) instructions for use.
  • the contents of the kit can be lyophilized, and the kit can additionally contain a suitable solvent for reconstitution of the lyophilized components.
  • the liquid solution can be an aqueous solution, for example a sterile aqueous solution.
  • the expression construct may be formulated into a pharmaceutically acceptable syringeable composition.
  • the container means may itself be an inhalant, syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an affected area of the animal, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit.
  • the components of the kit may also be provided in dried or lyophilized forms. When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent. It is envisioned that the solvent also may be provided in another container means.
  • kits of the invention also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal.
  • an instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eye dropper or any such medically approved delivery vehicle.
  • the invention described herein may include one or more range of values (eg. Size, displacement and field strength etc).
  • a range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. Hence “about 80 %” means “about 80 %” and also “80 %”.
  • Patent law e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of” and “consists essentially of” have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
  • Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.
  • active agent may mean one active agent, or may encompass two or more active agents.
  • Example 1 Clinical study examining the effect of a CCR2 antagonist in patients with ARDS as a result of COVID-19.
  • the study may be a stand-alone study of a CCR2 antagonist or may be part of a larger study testing other therapeutics, including an angiotensin receptor blocker.
  • One example may be a multi-centre, adaptive, open-label or placebo-controlled study that recruits participants admitted to hospital with ARDS associated with COVID-19.
  • the treatment arm for a CCR2 antagonist expected to be approximately 500 patients.
  • Another example may be a multi-centre, multiple-arm, parallel assignment, randomized, open-label or placebo-controlled study that recruits patients admitted to hospital with ARDS associated with COVID-19. This study would have approximately 500 to 1000 patients per treatment arm.
  • Table 2 Study of the effect of a CCR2 antagonist in patients with community-acquired pneumonia
  • Example 2 Clinical study examining the effect of a CCR2 antagonist in patients with ARDS associated with COVID-19 who are released from hospital.
  • ARDS acute respiratory distress syndrome
  • the study assesses the effect of a CCR2 antagonist in this population.
  • the study may be a stand- alone study of a CCR2 antagonist or may be part of a larger study testing other therapeutics, including an angiotensin receptor blocker.
  • One example may be a multi-centre, open-label or placebo-controlled study that recruits participants released from hospital following ARDS associated with COVID-19.
  • the treatment arm for a CCR2 antagonist expected to be approximately 500 to 1000 patients.
  • Table 3 Study of the effect of a CCR2 antagonist in patients recovering from ARDS associated with COVID-19 and following release from hospital
  • Example 3 Clinical study examining the effect of a CCR2 antagonist in patients with CAP associated with COVID-19 prior to hospitalisation.
  • the study assesses the effect of a CCR2 antagonist on the recovery of patients upon diagnosis of CAP associated with COVID-19 prior to hospitalisation, and the impact on the duration of CAP.
  • the study may be a stand-alone study of a CCR2 antagonist or may be part of a larger study testing other therapeutics, including an angiotensin receptor blocker.
  • One example may be a multi-centre, open-label or placebo-controlled study that recruits participants diagnosed with CAP associated with COVID-19 upon diagnosis.
  • the treatment arm for a CCR2 antagonist expected to be approximately 500 to 1000 patients.
  • Table 4 Study of the effect of a CCR2 antagonist in patients diagnosed with ARDS associated with COVID-19 prior to hospitalisation
  • Example 4 Clinical study examining the effect of a CCR2 antagonist in patients with COVID-19 respiratory complications, prior to the onset of Acute Respiratory Distress Syndrome (ARDS)
  • the study is a Phase 2/3 assessment of the effect of a CCR2 antagonist on patients with COVID-19 respiratory complications, prior to the onset of Acute Respiratory Distress Syndrome (ARDS).
  • the study may be a stand-alone study of a CCR2 antagonist or may be part of a larger study testing other therapeutics, including an angiotensin receptor blocker.
  • One example may be a prospective, multi-centre, randomised, double blind, placebo-controlled study that recruits participants diagnosed with COVID-19 respiratory complications.
  • the treatment arm for a CCR2 antagonist is expected to be approximately 600 patients.
  • the aim of this study is to evaluate the safety and efficacy of dual treatment with repagermanium and an AT 1 R blocker compared to placebo for patients hospitalised for management of COVID-19.
  • the safety and efficacy of dual treatment with repagermanium and candesartan will be assessed by the Clinical Health Score at day 14.
  • This Clinical Health Score is determined within a 7-point ordinal scale of health status which is a modified version of the 9-point score developed by the WHO for Coronavirus Disease 2019 (COVID-19) trials. A single score will be reported with higher values corresponding to worse symptoms.
  • the ordinal scale is an assessment of the clinical status of the participant at the first assessment for the day, measured at Day 14 after the date of randomisation.
  • 7-point ordinal scale of health status 1. Not hospitalised, no limitations on activities. 2. Not hospitalised, limitation on activities. 3. Hospitalised, not requiring supplemental oxygen. 4. Hospitalised, requiring supplemental oxygen. 5. Hospitalised, on non-invasive ventilation or high-flow oxygen devices. 6. Hospitalised, on invasive mechanical ventilation or ECMO. 7. Death.
  • the secondary objectives are to evaluate the safety and efficacy of dual treatment with repagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by: ⁇ Clinical Health Score at day 28.
  • ICU admission incidence in days 0-28.
  • Death incidence in days 0-28).
  • Time to death assessed from hospital admission to death.
  • Acute Kidney Injury incidence in days 0-28.
  • Respiratory Failure incidence in days 0-28).
  • Length of hospital admission days of inpatient stay from admission to discharge or death.
  • ICU Admission days in ICU from admission to transfer to ward or death).
  • the specific safety objectives are to evaluate the safety of dual treatment with epagermanium and candesartan in patients hospitalised with COVID-19 disease, assessed by incidence of pre-specified clinical events: ⁇ Hypotension, requiring an urgent or non-urgent intervention (e.g., reduction in dose or cessation of anti-hypertensive, vasopressors, intravenous fluids). Incidence in days 0-28.
  • CLARITY 2.0 is a prospective, Multi-Centre, Multi-Arm Multi-Stage Randomised, Double Blind, Placebo Controlled Phase II Trial, utilising adaptive sample size re-estimation. Stage 1 will include approximately 600 participants prior to a review of accumulated data and expansion to Stage 2 Phase III study.
  • SBP Systolic Blood Pressure
  • Randomisation Participants will be randomised by their treating team. Through the randomisation process the participant will be assigned a treatment arm. Treatment should be commenced as soon as possible and within one day after randomisation. Participants will be encouraged to continue in the trial, even if they withdraw from the randomised treatment allocation, to enable intention-to-treat analyses. Initially, treatment allocation will be with a 1:1:1 block randomisation between three arms, stratified by centre. TREATMENT PLAN Treatments [00171] The intervention being investigated in this trial is a dual therapy of candesartan and repagermanium. [00172] Candesartan is an ARB.
  • ARB treatment is commonly used in the management of hypertension, or for the prevention of progression of diabetic kidney disease or secondary prevention of cardiovascular events.
  • Repagermanium is a CCR2 antagonist with an extensive safety database and, unlike many immune modulators, has a low AE profile. When administered concurrently with an ARB, repagermanium is designed to inhibit recruitment of monocytes via both the AT1R and CCR2 pathways implicated in the inflammatory cytokine environment of respiratory distress.
  • Study Treatment [00174] Participants will be randomized to one of three arms described in Table 1, including repagermanium, or matched placebo, and candesartan, or matched placebo. Table 5: Trial Arms treatment [00175] The dose of repagermanium will be delivered as 120mg capsules given twice a day.
  • the dose will not be changed during the trial.
  • the starting dose of candesartan will be 4mg given twice a day.
  • the dose will be titrated in accordance with the algorithm presented in Figure 2.
  • Respiratory & COVID-19 Care For patients within this trial, background care and respiratory management will be according to local site regulations, recommendations and protocol in the setting of the pandemic. For patients within this trial, background care must include local investigations of Blood Pressure, Potassium and Renal Function as directed within the schedule of assessments. [00177] Patient safety is the primary responsibility of the treating clinician, as such their discretion should determine the course of action for the management of toxicities.
  • NSAIDs patients should be advised not to take NSAIDs whilst they are receiving treatment in the trial. This includes Nurofen, Ibuprofen, Advil, Voltaren and Mobic. Use of Paracetamol or Aspirin is permitted. [00179] Any other BP-lowering medication can continue except in the setting of hypotension. Compliance [00180] Participants and trial sites are encouraged to maintain appropriate treatment with the study intervention without interruption. Where treatment is missed or discontinued for any reason, relevant information should be documented. An intention-to-treat analysis will be performed on this trial data. Screening [00181] Potential participants will be screened within the 10 days prior to randomisation to ensure they meet all the inclusion criteria and do not meet any of the exclusion criteria as described above.
  • SARS-CoV-2 test within 10 days prior to randomisation, blood pressure, serum potassium (test performed or on record within the 3 months prior to randomisation) and eGFR (test performed or on record within the 3 months prior to randomisation).
  • Baseline Assessment [00182] Demographics and medical history assessment including details of the SARS- CoV-2 test and results, blood pressure, electrocardiogram (ECG), date of birth, sex, weight, height, smoking history, pregnancy test status (for women younger than 51 years), comorbidities, concomitant medications, and most recent blood test results. Ethnicity will be recorded.
  • Health status assessment including assessment of hospital admission status, ventilation status, supplemental oxygen status, intensive care unit status, and mortality status and collection of concomitant medications will be undertaken from baseline to day 28 from commencement of study treatment.
  • Blood tests will be undertaken at baseline, then days 1 , 3, 5, 7, 9 and 14 from commencement of study treatment. Blood tests will include Potassium, Serum Creatinine, Creatinine Kinase, estimated Glomerular Filtration Rate (using CKD-EPI creatinine equation), White Blood Cell Count, Neutrophil Count, Lymphocyte Count, D- Dimer, C-Reactive Protein, Aspartate Aminotransferase and Alanine Aminotransferase.
  • Participants will be followed up for 180 days after randomisation to reach the study endpoint.
  • the health status assessment measurement will be undertaken at 60 days, 90 days and 182 days and can be done by phone or clinic visit. Each visit will occur within a 7-day window of the scheduled visit date. Safety events will be reportable from initiation of trial treatment until day 60.
  • the primary endpoint is a Clinical Health Score, determined within a 7-point ordinal scale of clinical health status as described above which is a modified version of the 9- point score developed by the WHO for Coronavirus Disease 2019 (COVID-19) trials. A single score will be reported with higher values corresponding to worse symptoms.
  • the ordinal scale is an assessment of the clinical status of the participant at the first assessment for the day, measured at Day 14 after the date of randomisation.
  • Clinical assessment includes review of hospital medical records, following admission by the investigator, for Clinical Health Score events at day 14 (including hospitalisation, use of oxygen, ventilation, ECMO or death due to any cause). Where the participant has been discharged, Clinical Health Score events will be confirmed by the participant (by phone or clinic visit) or local General Practitioner.
  • Clinical assessment includes review of hospital medical records, following admission by the investigator, for Clinical Health Score events at day 28 (including hospitalisation, use of oxygen, ventilation, ECMO or death due to any cause). Where the participant has been discharged, Clinical Health Score events will be confirmed by the participant (by phone or clinic visit) or local General Practitioner. Community-based death events will be confirmed with the participant’s local General Practitioner in local medical records.
  • Intensive Care Unit (ICU) admission [00189] Incidence in days 0-28. Clinical assessment includes review of hospital medical records following admission by the investigator or notification of admission by the participant or local General Practitioner for ICU admission (for any reason).
  • AKI is defined by the KDIGO criteria as an increase in serum creatinine by ⁇ 0.3mg/dL within 48 hours or an increase in serum creatinine ⁇ 1.5 times from baseline within the last 7 days or urine output ⁇ 0.5 mL/kg/h for 6 hours.
  • Community-based AKI events will be confirmed with the participant’s local General Practitioner in local medical records.
  • Respiratory Failure [00193] Incidence in days 0-28. Clinical assessment includes review of hospital medical records following admission by the investigator or notification of respiratory failure events by the participant or local General Practitioner. Community-based respiratory failure events will be confirmed with the participant’s local General Practitioner in local medical records.
  • Length of hospital admission [00194] Days of inpatient stay from admission to discharge or death.
  • Clinical assessment includes review of hospital medical records following admission by the investigator or notification of hospital admission by the participant or local General Practitioner. Length of ICU admission [00195] Days in ICU from admission to transfer to ward or death. Clinical assessment includes review of hospital medical records following admission by the investigator or notification of overnight admissions to ICU by the participant or local General Practitioner. Requirement of ventilatory support [00196] Count of days with ventilation in days 0-28. Clinical assessment includes review of hospital medical records following admission by the investigator or notification of episodes of ventilatory support by the participant or local General Practitioner. Ventilatory support is defined as the delivery of oxygen via invasive or non- invasive ventilation. Requirement of dialysis [00197] Count of days with dialysis in days 0-28.
  • Clinical assessment includes review of hospital medical records following admission by the investigator or notification of episodes of dialysis support by the participant or local General Practitioner. Dialysis support is defined as any occurrence of haemodialysis or peritoneal dialysis. Community-based dialysis will be confirmed with the participant’s local General Practitioner in local medical records.
  • Clinical Health Score at day 60 [00198] Clinical assessment includes phone or clinic visit for Clinical Health Score events at day 60, including hospital admission (for any reason) or death (due to any cause). Community-based death events will be confirmed with the participant’s local General Practitioner in local medical records.
  • Clinical Health Score at day 90 [00199] Clinical assessment includes phone or clinic visit for Clinical Health Score events at day 90, including hospital admission (for any reason) or death (due to any cause).
  • Clinical Health Score at day 180 [00200] Clinical assessment includes phone or clinic visit for Clinical Health Score events at day 180, including hospital admission (for any reason) or death (due to any cause). Community-based death events will be confirmed with the participant’s local General Practitioner in local medical records. Safety objectives and measures Hypotension [00201] Incidence in days 0-28. Clinical assessment includes review of hospital medical records following admission by the investigator or notification of hypotensive events (requiring an urgent or non-urgent intervention) by the participant or local General Practitioner.
  • Hypotension is defined as blood pressure readings ⁇ 90 mmHg systolic or ⁇ 60 mmHg diastolic; urgent or non-urgent intervention includes, but is not limited to, reduction in dose or cessation of anti-hypertensives, vasopressors, intravenous fluids. Community-based hypotensive events will be confirmed with the participant’s local General Practitioner in local medical records.
  • Hyperkalaemia [00202] Incidence in days 0-28. Clinical assessment includes review of hospital medical records following admission by the investigator or notification of hyperkalemic events by the participant or local General Practitioner. Hyperkalaemia is defined as a K>5.5-6.0 mmol/L and requiring an intervention including hospitalisation, or K>6.0 mmol/L.
  • LFTs Liver Function Tests
  • Incidence in days 0-28 Incidence in days 0-28.
  • Clinical assessment includes review of hospital medical records following admission by the investigator or notification of deranged LFTs by the participant or local General Practitioner.
  • Deranged LFTs is defined as ALT or AST >ULN or >1.5 times baseline.
  • Community based LFT derangement will be confirmed with the participant’s local General Practitioner in local medical records / pathology reports.
  • Exploratory objective and measures Incidence of hospital readmission [00204] Admission for overnight stay up to day 90 following initial hospital discharge.
  • Clinical assessment includes review of hospital medical records to day 90 from primary admission at randomisation.
  • STUDY TREATMENT SUPPLY Investigational Arm Treatment [00205] Participants will receive candesartan 4mg tablets and repagermanium 120mg capsules in the study. [00206] Candesartan will be commenced at a daily dose of 8mg, titrated in accordance with the algorithm presented in Figure 2. Repagermanium will be commenced at a fixed daily dose of 240mg. Control Arms Treatment Participants will receive: 1. Candesartan 4mg tablets and placebo repagermanium capsules. Candesartan will be commenced at a daily dose of 8mg, titrated in accordance with the algorithm presented in Figure 2.
  • Placebo repagermanium capsules will be commenced at the fixed twice daily regimen. OR 2. Placebo [candesartan] tablets and Placebo repagermanium capsules. Candesartan placebo tablets will be commenced at a twice daily regimen, titrated in accordance with the algorithm presented in Figure 2. Placebo [repagermanium] capsules will be commenced at the fixed twice daily regimen.
  • Treatment Administration [00207] The investigational medicinal product (IMP) will be self-administered, within an hour of eating food, by participants who will be directed to take the IMP each day at approximately the same time (e.g., 9:00am and 7:00pm ⁇ 1 hour). STATISTICAL CONSIDERATIONS Sample Size [00208] Stage 1 of the trial will recruit 600 participants.
  • Stage 2 of the trial will be conducted using Bayesian methods, with rules determined from simulated analyses for stopping rules on efficacy, futility, and harm. Adaptive sample size estimation will be employed and detailed within an updated statistical considerations section, following completion of trial simulations.
  • Statistical Analysis [00211] This study will use Bayesian principles and Monte Carlo methods to evaluate the outcomes of interest. All inferences will be based on posterior distributions of the model parameters. Trial decisions will be based on the posterior and predictive distributions.
  • the estimated treatment effect on the primary endpoint will be expressed as the common odds ratio, corresponding to the odds of a better outcome in the investigational arm versus each comparator arm on the 7-point ordinal scale at Day 14, and its 95% credible interval. This will be modelled using a proportional odds logistic regression model. Details will be provided in the statistical analysis plan which will be completed prior to any analysis of the data. [00213] The assessment of the primary endpoint at Day 14 reflects the timeframe within which most SARS-CoV-2-positive patients have either developed severe disease or begun to recover. [00214] The primary analysis will be an ITT analysis, whereby comparisons will be made between all participants randomized to the treatment arms and who have passed the primary endpoint, irrespective of whether they received their allocated treatment. [00215] To explore the power achieved with the sample size, extensive simulations will be performed under various assumptions. Details of these simulations and their underlying assumptions will be provided in the statistical analysis plan.
  • Kidney disease is associated with in-hospital death of patients with COVID-19. [published online ahead of print March 20, 2020]. Kidney International.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de traitement ou de soulagement du syndrome de détresse respiratoire aiguë (SDRA) comprenant les étapes consistant à administrer à un sujet une quantité thérapeutiquement efficace d'au moins un inhibiteur de la voie du récepteur 2 de la chimiokine (CCR2) ou un sel pharmaceutiquement acceptable de celui-ci.
PCT/AU2021/050403 2020-05-06 2021-05-03 Traitement du syndrome de détresse respiratoire aiguë induite par un virus Ceased WO2021222971A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063021085P 2020-05-06 2020-05-06
US63/021,085 2020-05-06
US202063024357P 2020-05-13 2020-05-13
US63/024,357 2020-05-13

Publications (1)

Publication Number Publication Date
WO2021222971A1 true WO2021222971A1 (fr) 2021-11-11

Family

ID=78467660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2021/050403 Ceased WO2021222971A1 (fr) 2020-05-06 2021-05-03 Traitement du syndrome de détresse respiratoire aiguë induite par un virus

Country Status (1)

Country Link
WO (1) WO2021222971A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012094703A1 (fr) * 2011-01-11 2012-07-19 Dimerix Bioscience Pty Ltd Polythérapie
WO2012171863A1 (fr) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh Nouveaux antagonistes sélectifs de ccr2
WO2013144563A1 (fr) * 2012-03-30 2013-10-03 Ucl Business Plc Traitement d'une inflammation aiguë dans les voies respiratoires
WO2016113205A1 (fr) * 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Pentafluoréthylpyrimidinones substituées et leur utilisation
WO2019126431A1 (fr) * 2017-12-22 2019-06-27 Chemocentryx, Inc. Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
WO2021056051A1 (fr) * 2019-09-26 2021-04-01 Dimerix Bioscience Pty Ltd Méthode et composition pour le traitement d'une maladie

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012094703A1 (fr) * 2011-01-11 2012-07-19 Dimerix Bioscience Pty Ltd Polythérapie
WO2012171863A1 (fr) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh Nouveaux antagonistes sélectifs de ccr2
WO2013144563A1 (fr) * 2012-03-30 2013-10-03 Ucl Business Plc Traitement d'une inflammation aiguë dans les voies respiratoires
WO2016113205A1 (fr) * 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Pentafluoréthylpyrimidinones substituées et leur utilisation
WO2019126431A1 (fr) * 2017-12-22 2019-06-27 Chemocentryx, Inc. Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
WO2021056051A1 (fr) * 2019-09-26 2021-04-01 Dimerix Bioscience Pty Ltd Méthode et composition pour le traitement d'une maladie

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Angiotensin-(1-7): A Comprehensive Review", vol. 22, 2019, SPRINGER, Cham , ISBN: 978-3-030-22695-4, article GISELLE S. MAGALHÃES; MARIA JOSE CAMPAGNOLE-SANTOS; MARIA DA GLÓRIA RODRIGUES-MACHADO: "Lung", pages: 131 - 152, XP009532128, DOI: 10.1007/978-3-030-22696-1_9 *
CAO ZHENG, LIU JING-LAN, WU SHEN, WANG QIAO: "Mechanism of MCP-1 in Acute Lung Injury and Advanced Therapy by Drug-Loaded Dextrin Nanoparticle", INTERNATIONAL JOURNAL OF POLYMER SCIENCE, HINDAWI PUBLISHING CORPORATION, vol. 2018, 27 September 2018 (2018-09-27), pages 1 - 7, XP055870666, ISSN: 1687-9422, DOI: 10.1155/2018/9269154 *
OKAMOTO MIKA; TOYAMA MASAAKI; BABA MASANORI: "The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 182, 30 July 2020 (2020-07-30), NL , XP086271081, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2020.104902 *
RAQUEL GUILLAMAT-PRATS, MARTA CAMPRUBÍ-RIMBLAS, NEUS TANTINYÀ, ANTONIO ARTIGAS: "Local depletion of the recruitment of macrophages reduces acute lung injury in rats", EUROPEAN RESPIRATORY JOURNAL, vol. 52, no. Suppl. 62, 2018, pages 1 - 2, XP009532087, ISSN: 0903-1936, DOI: 10.1183/13993003.congress-2018.PA4296 *
SHWETA CHOUDHARY, MALIK YASHPAL S., TOMAR SHAILLY: "Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in Silico Structure-Based Virtual Screening Approach", CHEMRXIV, 15 April 2020 (2020-04-15), pages 1 - 34, XP055726930, Retrieved from the Internet <URL:https://s3-eu-west-1.amazonaws.com/itempdf74155353254prod/12005988/Identification_of_SARS-CoV-2_Cell_Entry_Inhibitors_by_Drug_Repurposing_Using_in_Silico_Structure-Based_Virtual_Screening_v2.pdf> DOI: 10.26434/chemrxiv.12005988.v2 *
YANG, D. ; TONG, L. ; WANG, D. ; WANG, Y. ; WANG, X. ; BAI, C.: "Roles of CC chemokine receptors (CCRs) on lipopolysaccharide-induced acute lung injury", RESPIRATORY PHYSIOLOGY AND NEUROBIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 170, no. 3, 31 March 2010 (2010-03-31), NL , pages 253 - 259, XP027493735, ISSN: 1569-9048, DOI: 10.1016/j.resp.2010.02.002 *

Similar Documents

Publication Publication Date Title
US20240366570A1 (en) Method for treating inflammatory disorders
US20200000772A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
WO2021222972A1 (fr) Traitement du syndrome de détresse respiratoire aiguë
US20240173302A1 (en) Treatment of inflammatory diseases
US20240009191A1 (en) Method and composition for the treatment of disease
WO2021222971A1 (fr) Traitement du syndrome de détresse respiratoire aiguë induite par un virus
US20250049840A1 (en) Compositions comprising a chemokine receptor pathway inhibitor
WO2024026528A1 (fr) Régime posologique pour le traitement de la bpco
ES2770785T3 (es) Terapia de combinación
HK1192712B (en) Combination therapy
HK1192712A (en) Combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21800375

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21800375

Country of ref document: EP

Kind code of ref document: A1